Our Pipeline

Developing life-changing gene therapies for devastating neurological diseases.

Voyager’s product pipeline includes programs for Huntington’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS) called SOD1, Friedreich’s ataxia, and a vectorized antibody approach targeting tauopathies, such as Alzheimer’s disease. For each of these diseases, there is a dire need for new therapies. Depending on the disease, our gene therapies will use gene replacement, gene knockdown or our vectorized antibody approach. By significantly increasing or decreasing production of relevant proteins at targeted sites within the central nervous system, the goal is to make a meaningful impact on the lives of patients.